Terry Box, MD - Ogden Surgical
... CUPIC: Interim Analysis of TVR and BOC Use in Cirrhotic Early Access Program • Interim results of 455 patients presented at 16-20 wks – Encouraging virologic responses with triple therapy • ~ 80% treated with TVR-based therapy had undetectable HCV RNA at end of 16 wks of ongoing therapy • ~ 65% tre ...
... CUPIC: Interim Analysis of TVR and BOC Use in Cirrhotic Early Access Program • Interim results of 455 patients presented at 16-20 wks – Encouraging virologic responses with triple therapy • ~ 80% treated with TVR-based therapy had undetectable HCV RNA at end of 16 wks of ongoing therapy • ~ 65% tre ...
Document
... Marsch, LA, Bickel WK, Badger GJ, et al (2005) Comparison of pharmacological treatments for opioid-dependent adolescents. Arch Gen Psychiatry 62, 1157-1164. Mattick, RP, Kimber J, Breen C, and Davoli M (2004) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, ...
... Marsch, LA, Bickel WK, Badger GJ, et al (2005) Comparison of pharmacological treatments for opioid-dependent adolescents. Arch Gen Psychiatry 62, 1157-1164. Mattick, RP, Kimber J, Breen C, and Davoli M (2004) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, ...
Chapters 1 - Canadian Liver Foundation
... management of patients with chronic hepatitis C. HCV RNA testing should be performed using a sensitive quantitative assay (lower limit of detection ≤ 10-15 IU/mL) with a broad dynamic range. Standardized results should be expressed in IU/mL and be available within a maximum of 7 days in order to f ...
... management of patients with chronic hepatitis C. HCV RNA testing should be performed using a sensitive quantitative assay (lower limit of detection ≤ 10-15 IU/mL) with a broad dynamic range. Standardized results should be expressed in IU/mL and be available within a maximum of 7 days in order to f ...
antiviral treatment of hepatitis c in serbian prison setting
... because PEGIFN alfa-2b was not available. Because of an underlying disease most of our patients used psychiatric medications during hepatitis C treatment: benzodiazepine (89.5%), Methadone (9.3%), and antidepressant (12.5%). None of the patients used antipsychotic medication. In general, therapy was ...
... because PEGIFN alfa-2b was not available. Because of an underlying disease most of our patients used psychiatric medications during hepatitis C treatment: benzodiazepine (89.5%), Methadone (9.3%), and antidepressant (12.5%). None of the patients used antipsychotic medication. In general, therapy was ...
HEPATITIS A, B, C, D, E, G: AN UPDATE
... was originally used to treat HIV disease. For HBV, it is well tolerated, is given orally (100 mg/day), is relatively inexpensive ($7/day), has minimal side effects, and can be used in decompensated cirrhosis; however, it is associated with a high rate of drug resistance. Adefovir, a nucleotide analo ...
... was originally used to treat HIV disease. For HBV, it is well tolerated, is given orally (100 mg/day), is relatively inexpensive ($7/day), has minimal side effects, and can be used in decompensated cirrhosis; however, it is associated with a high rate of drug resistance. Adefovir, a nucleotide analo ...
Amiodarone Shared Care Guideline - Interface Pharmacist Network
... setting and the on-going combination should only be advised by a cardiologist. If concurrent use is required, reduce the previous the dose of digoxin by half and check the digoxin level during amiodarone initiation, or if concerns of digoxin toxicity. After discontinuation of amiodarone, reassess he ...
... setting and the on-going combination should only be advised by a cardiologist. If concurrent use is required, reduce the previous the dose of digoxin by half and check the digoxin level during amiodarone initiation, or if concerns of digoxin toxicity. After discontinuation of amiodarone, reassess he ...
ASSESSMENT OF INTERFERON, PEGINTERFERON, TENOFOVIR, ENTECAVIR, LAMIVUDINE
... Seven drugs currently available as therapeutic options for HBeAgpositive adults with hepatitis B and without cirrhosis were compared: 1) interferon alpha; 2) peginterferon alfa-2a; 3) peginterferon alfa-2b; 4) tenofovir; 5) entecavir; 6) lamivudine; and 7) adefovir. METHODS A Markov model of health ...
... Seven drugs currently available as therapeutic options for HBeAgpositive adults with hepatitis B and without cirrhosis were compared: 1) interferon alpha; 2) peginterferon alfa-2a; 3) peginterferon alfa-2b; 4) tenofovir; 5) entecavir; 6) lamivudine; and 7) adefovir. METHODS A Markov model of health ...
Urinary Metabolite Tests for Adherence to Direct
... the SPRINT-2 and RESPOND-2 trials. Adherence above 80% was reported for 63% of the treated patients in 1 trial and 71% in the other. For patients with adherence above 80%, the sustained virologic response (SVR) was 86% and 90% in the respective trials. In contrast, for patients with adherence below ...
... the SPRINT-2 and RESPOND-2 trials. Adherence above 80% was reported for 63% of the treated patients in 1 trial and 71% in the other. For patients with adherence above 80%, the sustained virologic response (SVR) was 86% and 90% in the respective trials. In contrast, for patients with adherence below ...
NEW THERAPIES FOR TREATMENT FOR HEPATITIS C KAPIL
... for telaprevir these are the ADVANCE, the ILLUMINATE and the REALIZE trials. Pretty fancy words right? The ADVANCE trial investigated the treatment for patients who are naïve meaning patients never treated before. And basically there was either 8 or 12 weeks of telaprevir depending on the response a ...
... for telaprevir these are the ADVANCE, the ILLUMINATE and the REALIZE trials. Pretty fancy words right? The ADVANCE trial investigated the treatment for patients who are naïve meaning patients never treated before. And basically there was either 8 or 12 weeks of telaprevir depending on the response a ...
Sovaldi - Gilead
... The proportion of subjects who permanently discontinued treatment due to adverse events was 4% for subjects receiving placebo, 1% for subjects receiving SOVALDI + ribavirin for 12 weeks, less than 1% for subjects receiving SOVALDI + ribavirin for 24 weeks, 11% for subjects receiving peginterferon al ...
... The proportion of subjects who permanently discontinued treatment due to adverse events was 4% for subjects receiving placebo, 1% for subjects receiving SOVALDI + ribavirin for 12 weeks, less than 1% for subjects receiving SOVALDI + ribavirin for 24 weeks, 11% for subjects receiving peginterferon al ...
Clinical Trial on treatment of Chronic Hepatitis B with IMMUNE
... clearly shows that greater effectiveness can be achieved with the addition of ImmuneAssist™ to the standard treatment protocols than can be provided by the conventional therapy alone in patients suffering from chronic hepatitis B. these results suggest that further research is indicated to determine ...
... clearly shows that greater effectiveness can be achieved with the addition of ImmuneAssist™ to the standard treatment protocols than can be provided by the conventional therapy alone in patients suffering from chronic hepatitis B. these results suggest that further research is indicated to determine ...
Treatment of Hepatitis C in Patients with HIV
... HCV genotype 1, 2, 3, or 4 were eligible. The HIV entry criteria required a CD4 count greater than 350 cells/mm3 if the patient was not taking antiretroviral therapy or at least 100 cells/mm3 if on antiretroviral therapy and an HIV RNA less than 50 copies/ml. The SVR 12 rates were excellent with the ...
... HCV genotype 1, 2, 3, or 4 were eligible. The HIV entry criteria required a CD4 count greater than 350 cells/mm3 if the patient was not taking antiretroviral therapy or at least 100 cells/mm3 if on antiretroviral therapy and an HIV RNA less than 50 copies/ml. The SVR 12 rates were excellent with the ...
INTERFERONS, ALPHA - DavisPlus
... Peginterferon alpha-2a: Treatment of: Chronic hepatitis C (alone or with ribavirin), Chronic hepatitis B. Interferon alpha-2b Treatment of: Hairy cell leukemia, Malignant melanoma, AIDS-related Kaposi’s sarcoma, Condylomata acuminata (intralesional), Chronic hepatitis B, Chronic hepatitis C (with or ...
... Peginterferon alpha-2a: Treatment of: Chronic hepatitis C (alone or with ribavirin), Chronic hepatitis B. Interferon alpha-2b Treatment of: Hairy cell leukemia, Malignant melanoma, AIDS-related Kaposi’s sarcoma, Condylomata acuminata (intralesional), Chronic hepatitis B, Chronic hepatitis C (with or ...
Session 5 Infective hepatitis
... Other factors HIV Chronic HBV Age > 40 when infected Male ...
... Other factors HIV Chronic HBV Age > 40 when infected Male ...
Treatment of Hepatitis C in Patients with HIV
... HCV genotype 1, 2, 3, or 4 were eligible. The HIV entry criteria required a CD4 count greater than 350 cells/mm3 if the patient was not taking antiretroviral therapy or at least 100 cells/mm3 if on antiretroviral therapy and an HIV RNA less than 50 copies/ml. The SVR 12 rates were excellent with the ...
... HCV genotype 1, 2, 3, or 4 were eligible. The HIV entry criteria required a CD4 count greater than 350 cells/mm3 if the patient was not taking antiretroviral therapy or at least 100 cells/mm3 if on antiretroviral therapy and an HIV RNA less than 50 copies/ml. The SVR 12 rates were excellent with the ...
New therapeutic agents marketed in 2014: Part 3 - learn
... have been associated with weight gain during treatment. Conversely, many patients treated with a GLP-1 agonist experience weight loss. Although dulaglutide and albiglutide have not been directly compared in clinical studies, the data from studies in which the two drugs were evaluated on an individua ...
... have been associated with weight gain during treatment. Conversely, many patients treated with a GLP-1 agonist experience weight loss. Although dulaglutide and albiglutide have not been directly compared in clinical studies, the data from studies in which the two drugs were evaluated on an individua ...
Hepatitis C Virus Direct-Acting Antiviral Drug Interactions - IAS-USA
... liver transplant patients. Cyclosporine is a potent CYP3A4 and P-gp inhibitor, and coadministration results in an approximately 6-fold increase in simeprevir exposure; therefore, coadministration of cyclosporine and imeprevir is not recommended. Coadministration of simeprevir and tacrolimus results ...
... liver transplant patients. Cyclosporine is a potent CYP3A4 and P-gp inhibitor, and coadministration results in an approximately 6-fold increase in simeprevir exposure; therefore, coadministration of cyclosporine and imeprevir is not recommended. Coadministration of simeprevir and tacrolimus results ...
Product Information for sofosbuvir
... PM-2013-01283-1-2 Final 5 August 2014. This Product Information was approved at the time this AusPAR was published. ...
... PM-2013-01283-1-2 Final 5 August 2014. This Product Information was approved at the time this AusPAR was published. ...
Ribavirin (Rebetol, Copegus)
... or circulation problems (cerebral vascular disease) ribavirin should be used with careful consideration as the anemia could trigger a lack an insufficient oxygen in a portion of the heart muscle (ischemia). Strokes also have been reported during combination therapy with alpha interferon and ribaviri ...
... or circulation problems (cerebral vascular disease) ribavirin should be used with careful consideration as the anemia could trigger a lack an insufficient oxygen in a portion of the heart muscle (ischemia). Strokes also have been reported during combination therapy with alpha interferon and ribaviri ...
Hepatitis in HIV/AIDS - Vanderbilt University Medical Center
... 2D6 minor; OBV: amide hydrolysis • Drug interaction potential: PTV levels may be ↑ or ↓ by drugs that inhibit or induce metabolism. RTV is a potent CYP3A4 inhibitor. OBV and PTV also inhibit UGT1A1. ◦◦ The dose of ritonavir used for boosting of HIV protease inhibitors may need to be adjusted (or he ...
... 2D6 minor; OBV: amide hydrolysis • Drug interaction potential: PTV levels may be ↑ or ↓ by drugs that inhibit or induce metabolism. RTV is a potent CYP3A4 inhibitor. OBV and PTV also inhibit UGT1A1. ◦◦ The dose of ritonavir used for boosting of HIV protease inhibitors may need to be adjusted (or he ...
MID2006-AntiviralAgt..
... – Flavi-, paramyxo-, bunya-, arena-, retro-, herpes-, adeno-, and poxviruses ...
... – Flavi-, paramyxo-, bunya-, arena-, retro-, herpes-, adeno-, and poxviruses ...
Anti-Herpesvirus Agents
... Mechanism of action complex Triphosphorylated by host cell enzymes For influenza Ribavirin-TP interferes with capping and elongation of mRNA and may inhibit viral RNA polymerase For other agents Ribavirin-MP inhibits inosine-5’-monophosphate dehydrogenase depleting intracellular nucleotide ...
... Mechanism of action complex Triphosphorylated by host cell enzymes For influenza Ribavirin-TP interferes with capping and elongation of mRNA and may inhibit viral RNA polymerase For other agents Ribavirin-MP inhibits inosine-5’-monophosphate dehydrogenase depleting intracellular nucleotide ...
Viekira Pak™ Prior Authorization Worksheet for Prescribers
... Paritaprevir and ritonavir are primarily metabolized by CYP3A enzymes and dasabuvir is metabolized by the CYP2C8 enzyme. Coadministration of the product with drugs that are highly dependent on CYP3A for clearance, strong inducers of CYP3A or CYP2D8, and strong inhibitors of the CYP2D8 enzyme are con ...
... Paritaprevir and ritonavir are primarily metabolized by CYP3A enzymes and dasabuvir is metabolized by the CYP2C8 enzyme. Coadministration of the product with drugs that are highly dependent on CYP3A for clearance, strong inducers of CYP3A or CYP2D8, and strong inhibitors of the CYP2D8 enzyme are con ...
Hepatitis
... 105 kg; and 1,400 mg for patients weighting >105 kg but < 125 kg) was more effective (Jacobson et al, 2007). ...
... 105 kg; and 1,400 mg for patients weighting >105 kg but < 125 kg) was more effective (Jacobson et al, 2007). ...
Sofosbuvir
Sofosbuvir (brand names Sovaldi, Hepcinat, Resof, Hepcvir, SoviHep) is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of HCV.Sofosbuvir inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences.In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4. In 2014 a combination of sofosbuvir with the viral NS5A inhibitor ledipasvir was approved. This latter combination provides high cure rates in people infected with genotype 1 (the most common subtype in the U.S., Japan, and much of Europe) without the use of interferon, irrespective of prior treatment failure or the presence of cirrhosis.The price of sofosbuvir, quoted in various media sources as $84,000 to $168,000 for a course of treatment in the U.S., £35,000 in the UK for 12 weeks has engendered considerable controversy. In September 2014, Gilead announced that it would permit generic manufacturers to sell sofosbuvir in 91 developing countries and that it would sell a name brand version of the product in India for approximately $300 per course of treatment.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.